Company news

Vertex Pharmaceuticals Incorporated news in 2025

Vertex Pharmaceuticals Incorporated's news releases, calls and decks from 2025, newest first.

View company

Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12

December 21, 2025

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions

December 6, 2025

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions

December 5, 2025

Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3

November 19, 2025

Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3

November 18, 2025

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

November 7, 2025

Vertex Reports Third Quarter 2025 Financial Results

November 2, 2025

Vertex to Participate in the UBS Global Healthcare Conference on November 11

October 26, 2025

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

October 23, 2025

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

October 22, 2025

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week

October 16, 2025

Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors

October 9, 2025

Vertex to Announce Third Quarter 2025 Financial Results on November 3rd

October 5, 2025

Vertex Announces Key Advancements Across Kidney Portfolio

September 24, 2025

Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain

September 23, 2025

Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain

September 22, 2025

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy

September 18, 2025

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy

September 17, 2025

Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis

September 10, 2025

US Cystic Fibrosis Therapeutics Market Forecast and Company Analysis Report 2025-2033 Featuring Vertex, Abbvie, Novartis, Gilead Sciences, Viatris, Pfizer, AstraZeneca, and F. Hoffmann-La Roche

September 10, 2025

National Advertising Division Refers Maze Therapeutics to Regulatory Authorities for Failure to Respond to Inquiry

August 27, 2025

Vertex to Participate in Upcoming September Investor Conferences

August 19, 2025

Vertex Reports Second Quarter 2025 Financial Results

August 3, 2025

Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain

August 3, 2025

Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis

July 22, 2025

Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

July 14, 2025

Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX(TM), a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain

July 14, 2025

Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain

July 13, 2025

Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

July 13, 2025

Vertex to Announce Second Quarter 2025 Financial Results on August 4th

July 7, 2025

Vertex Presents Longer-Term Data at the 2025 European Hematology Association (EHA) Congress Demonstrating Durability of CASGEVY® and Provides Update on Expanding Global Access to CASGEVY

July 3, 2025

Vertex Presents Longer-Term Data at the 2025 European Hematology Association (EHA) Congress Demonstrating Durability of CASGEVY® and Provides Update on Expanding Global Access to CASGEVY

July 3, 2025

Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

July 1, 2025

Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

June 30, 2025

Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea

June 22, 2025

Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions

June 19, 2025

Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference

June 6, 2025

Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference

June 5, 2025

Vertex to Participate in Upcoming Investor Conferences

May 14, 2025

Vertex Reports First Quarter 2025 Financial Results

May 4, 2025

Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

April 10, 2025

European Commission Approves Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis

April 7, 2025

Vertex to Announce First Quarter 2025 Financial Results on May 5th

April 6, 2025

European Commission Approves Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis

April 6, 2025

Vertex Announces Program Updates for Type 1 Diabetes Portfolio

March 27, 2025

Vertex Announces UK MHRA Approval of ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis

March 7, 2025

Vertex Announces UK MHRA Approval of ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis

March 6, 2025

Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations

February 28, 2025

Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations

February 27, 2025

Vertex to Participate in Upcoming March Investor Conferences

February 17, 2025

Older news releases →

Calls in 2025

Decks in 2025